DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Pasireotide
OtherFDA approvedRx required

Pasireotide

Also known as: Signifor · Signifor LAR
Brands: Signifor · Signifor LAR

Cyclohexapeptide somatostatin analog approved for Cushing disease and acromegaly.

A
Grade A
Multiple human RCTs
Human studies24
PubMed citations26
Routesubcutaneous, intramuscular
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Binds four of the five somatostatin receptor subtypes (SSTR1, 2, 3, 5) with highest affinity for SSTR5. Broader receptor profile than octreotide.

Evidence summary

24
Human studies
26
PubMed citations
25
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneousintramuscular

Side effects & safety

From the FDA label
Source
abdominal painarthralgiaastheniaback painconstipationdecreased appetitediarrheadizzinessfatigueheadachehypoglycemiainsomnianauseapancreatitispruritusvomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for Cushing disease and acromegaly (Signifor, Signifor LAR)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT06784752A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)Recruiting · Phase 3 · Somatostatin Receptor Positive (SSTR+) · n=240NCT06295952Pasireotide Treatment for Patients With Prolactinomas Who Need Treatment Beyond Dopamine Agonist TherapyRecruiting · Phase 2 · Prolactin-Producing Pituitary Tumor · n=10NCT07312643A Phase 1, Open-label, Randomized, Crossover Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an AmpuleCompleted · Phase 1 · Pharmacokinetics · n=40NCT03972488A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive Not Recruiting · Phase 3 · Gastro-enteropancreatic Neuroendocrine Tumor · n=226NCT02713776Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled StudyCompleted · Phase 2 · Enterostomy · n=57NCT05928390A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaActive Not Recruiting · Phase 2 · Post-Bariatric Hypoglycemia · n=93NCT07179926Effects of Pasireotide Lar Therapy on Bone MetabolismRecruiting · Acromegaly Due to Pituitary Adenoma · n=120NCT01313559An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer PatientsTerminated · Phase 2 · Castrate Resistant Prostate Cancer · n=6NCT03847207A Three-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of HTL0030310 in Healthy SubjectsCompleted · Phase 1 · Healthy · n=42NCT06456359Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell TumorRecruiting · Phase 2 · Desmoplastic Small Round Cell Tumor · n=28NCT02310269Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)Completed · Cushings Disease · n=152NCT01794793An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide TreatmentCompleted · Phase 4 · Cushing's Disease · n=337

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41904067Samson SL · Resistant prolactinomas.Best practice &amp; research. Clinical endocrinology &amp; metabolism (2026)PMID 40974037van der Groef R, Veldhuijzen van Zanten S et al. · Long-term antitumour effects of pasireotide in acromegaly.European journal of endocrinology (2025)HumanPMID 39788490Chai J, Tang Y et al. · Advances in pharmacological treatment of Cushing's disease.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences (2025)HumanPMID 39116368Zhang B, Xue L et al. · Structure and Function of Somatostatin and Its Receptors in Endocrinology.Endocrine reviews (2025)HumanPMID 38078447Kasuki L, Lamback E et al. · Biomarkers of response to treatment in acromegaly.Expert review of endocrinology &amp; metabolism (2024)HumanPMID 39526050Violetis O, Alexandraki KI · New Trends in Treating Cushing's Disease.TouchREVIEWS in endocrinology (2024)HumanPMID 38290866Bhat SZ, Salvatori R · Current role of pasireotide in the treatment of acromegaly.Best practice &amp; research. Clinical endocrinology &amp; metabolism (2024)HumanPMID 37689507Shimon I · Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.Archives of medical research (2023)HumanPMID 37316636Gadelha MR, Kasuki L · Refractory somatotroph adenomas.Pituitary (2023)HumanPMID 35670988Gadelha MR, Wildemberg LE et al. · Pituitary acting drugs: cabergoline and pasireotide.Pituitary (2022)HumanPMID 33796079Puig-Domingo M, Bernab&#xe9;u I et al. · Pasireotide in the Personalized Treatment of Acromegaly.Frontiers in endocrinology (2022)HumanPMID 35931640Chiloiro S, Bianchi A et al. · Second line treatment of acromegaly: Pasireotide or Pegvisomant?Best practice &amp; research. Clinical endocrinology &amp; metabolism (2022)HumanPMID 34934445Valea A, Sandru F et al. · Aggressive prolactinoma (Review).Experimental and therapeutic medicine (2021)PMID 30608534Coopmans EC, Muhammad A et al. · How to Position Pasireotide LAR Treatment in Acromegaly.The Journal of clinical endocrinology and metabolism (2020)HumanPMID 32440136Corica G, Ceraudo M et al. · Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management (2020)HumanPMID 30033041Feelders RA, Newell-Price J et al. · Advances in the medical treatment of Cushing's syndrome.The lancet. Diabetes &amp; endocrinology (2020)HumanPMID 32121432Gomes-Porras M, C&#xe1;rdenas-Salas J et al. · Somatostatin Analogs in Clinical Practice: a Review.International journal of molecular sciences (2020)HumanPMID 30899019Colao A, Grasso LFS et al. · Acromegaly.Nature reviews. Disease primers (2019)HumanPMID 29595102Sawicka-Gutaj N, Owecki M et al. · Pasireotide - Mechanism of Action and Clinical Applications.Current drug metabolism (2018)HumanPMID 28170483Molitch ME · Diagnosis and Treatment of Pituitary Adenomas: A Review.JAMA (2017)Human

Showing 20 of 26 papers. View all on PubMed →